Influence of CYP2C9 and VKORC1 polymorphisms on warfarin dose and anti-coagulative effect in Chinese population

Chinese Pharmaceutical Journal

Volumn 45, Issue 21, 2010, Pages 1628-1633

  Du, Liping ^a   Mei, Dan ^a   Liu, Changwei ^a   Liu, Bao ^a   Su, Wei ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

CYP2C9; Dosing regimen; Gene polymorphism; VKORC1; Warfarin

Indexed keywords

ALBUMIN; CYTOCHROME P450 2C9; PROTEIN; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX 1; WARFARIN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ANTICOAGULATION; ARTICLE; BODY HEIGHT; BODY WEIGHT; CHINESE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; GENDER; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

EID: 78649874990     PISSN: 10012494     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. ANSELL J, HIRSH J, HYLEK E, et al. Pharmacology and management of the vita min K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)[J]. Chest, 2008, 133(6 Suppl): 160S-198S.
2. ZHENG C, MEI D, GUAN H. Effect of CYP2C9 genetic polymorphisms on warfarin dosage and anticoagulation[J]. Chin Pharm J, 2008, 43(11): 862-865.
3. YUAN H Y, CHEN J J, LEE M T, et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity[J]. Hum Mol Genet, 2005, 14(13): 1745-1751.
4. VEENSTRA D L, YOU J H, RIEDER M J, et al. Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population[J]. Pharmacogenet Genomics, 2005, 15(10): 687-691.
5. RIEDER M J, REINER A P, GAGE B F, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose[J]. N Engl J Med, 2005, 352(22): 2285-2293.
6. SULLIVAN-KLOSE T H, GHANAYEM B I, BELL D A, et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism[J]. Pharmacogenetics, 1996, 6(4): 341-349.
7. YASAR U, ELIASSON E, DAHL M L, et al. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population[J]. Biochem Biophys Res Commun, 1999, 254(3): 628-631.
8. SCONCE E A, KHAN T I, WYNNE H A, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen[J]. Blood, 2005, 106(7): 2329-2333.
9. FURUYA H, FERNANDEZ-SALGUERO P, GREGORY W, et al. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy[J]. Pharmacogenetics, 1995, 5(6): 389-392.
10. ROST S, FREGIN A, IVASKEVICIUS V, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2[J]. Nature, 2004, 427(6974): 537-541.
11. LI T, CHANG C Y, JIN D Y, et al. Identification of the gene for vitamin K epoxide reductase[J]. Nature, 2004, 427(6974): 541-544.
12. REITSMA P H, VAN DER HEIJDEN J F, GROOT A P, et al. A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk[J]. Plos Med, 2005, 2(10): 996-998.
13. BODIN L, VERSTUYFT C, TREGOUET D A, et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as deter minants of acenocoumarol sensitivity[J]. Blood, 2005, 106(1): 135-140.
14. TANG H N, DU Y K, ZHANG Z G, et al. Correlation between warfarin maintenance dose with the polymorphisms of CYP2C9 and VKORC1 in Han and Uygur population on low anticoagulant level after mechanical heart valve prostheses implantation[J]. Chin Pharm Med Instrum, 2007, 2(4): 216-220.
15. MIAO L, YANG J, HUANG C, et al. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients[J]. Eur J Clin Pharmacol, 2007, 63(12): 1135-1141.
16. YACOBI A, UDALL J A, LEVY G. Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect[J]. Clin Pharmacol Ther, 1976, 19(5 Pt 1): 552-558.
17. PIROLI R J, PASSANANTI G T, SHIVELY C A, et al. Antipyrine and warfarin disposition in a patient with idiopathic hypoalbuminemia[J]. Clin Pharmacol Ther, 1981, 30(6): 810-816.
18. YOSHIZAWA M, HAYASHI H, TASHIRO Y, et al. Effect of VKORC1 -1639 G > A polymorphism, body weight, age, and serum albumin alterations on warfarin response in Japanese patients[J]. Thromb Res, 2009, 124(2): 161-166.
19. KRAGH-HANSEN U, BRENNAN S O, GALLIANO M, et al. Binding of warfarin, salicylate, and diazepam to genetic variants of human serum albumin with known mutations[J]. Mol Pharmacol, 1990, 379(2): 238-242.
20. WATANABE H, KRAGH-HANSEN U, TANASE S, et al. Conformational stability and warfarin binding properties of human serum albu min studied by recombinant mutants[J]. Biochem J, 2001, 357(Pt 1): 269-274.
21. KOHNKE H, SÖRLIN K, GRANATH G, et al. Warfarin dose related to apolipoprotein E (APOE) genotype[J]. Clin Pharmacol J, 2005, 61(5-6): 381-388.
22. WADELIUS M, CHEN L Y, DOWNES K, et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose[J]. Pharmacogenomics J, 2005, 5(4): 262-270.
23. CHEN L Y, ERIKSSON N, GWILLIAM R, et al. Gamma-glutamyl carboxylase (GGCX) microsatellite and warfarin dosing[J]. Blood, 2005, 106(10): 3673-3674.
24. CHEN K P. The disturbing present situation of anticoagulant therapy in China. [N/OL]. China Medical Tribune, 2008-5-29 (1108), [2008-6-23] http://www.cmt.com.cn/article/080529/a080529c0702.htm
25. KLEIN T E, ALTMAN R B, et al. International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data[J]. N Engl J Med, 2009, 360(8): 753-764.